IR-Med, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IR-Med, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.90M) | Apr 4, 2025 |
| FY2024 | Dec 31, 2023 | ($4.91M) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | ($4.73M) | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | ($3.72M) | May 11, 2023 |
| FY2021 | Dec 31, 2020 | ($752.0K) | Mar 31, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.94M) | Apr 4, 2025 |
| FY2024 | Dec 31, 2023 | ($4.91M) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | ($4.76M) | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | ($3.68M) | May 11, 2023 |
| FY2021 | Dec 31, 2020 | ($730.0K) | Mar 31, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $710.0K | Apr 4, 2025 |
| FY2024 | Dec 31, 2023 | $2.06M | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $1.89M | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | $1.42M | May 11, 2023 |
| FY2021 | Dec 31, 2020 | $409.0K | Mar 31, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.39M) | Apr 4, 2025 |
| FY2024 | Dec 31, 2023 | ($3.23M) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | ($3.38M) | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | ($2.48M) | May 11, 2023 |
| FY2021 | Dec 31, 2020 | ($402.0K) | Mar 31, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $2.0K | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $50.0K | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | $31.0K | May 11, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $251.0K | Apr 4, 2025 |
| FY2024 | Dec 31, 2023 | $999.0K | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $3.29M | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | $2.94M | May 11, 2023 |
| FY2021 | Dec 31, 2020 | $2.09M | Mar 31, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $545.0K | Apr 4, 2025 |
| FY2024 | Dec 31, 2023 | $634.0K | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $702.0K | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | $572.0K | May 11, 2023 |
| FY2021 | Dec 31, 2020 | $689.0K | Mar 31, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($294.0K) | Apr 4, 2025 |
| FY2024 | Dec 31, 2023 | $365.0K | Apr 4, 2025 |
| FY2024 | Dec 31, 2022 | $2.59M | Apr 4, 2025 |
| FY2023 | Dec 31, 2021 | $2.4K | Apr 8, 2024 |
| FY2022 | Dec 31, 2020 | $1.40M | May 11, 2023 |
| FY2021 | Dec 31, 2019 | ($81.0K) | Mar 31, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($16.74M) | Apr 4, 2025 |
| FY2024 | Dec 31, 2023 | ($14.84M) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | ($9.93M) | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | ($5.20M) | May 11, 2023 |
| FY2021 | Dec 31, 2020 | ($1.48M) | Mar 31, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $129.0K | Apr 4, 2025 |
| FY2024 | Dec 31, 2023 | $767.0K | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $3.00M | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | $2.82M | May 11, 2023 |
| FY2021 | Dec 31, 2020 | $1.87M | Mar 31, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 4, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | 0 | May 11, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 4, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 8, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 71.01M | Apr 4, 2025 |
| FY2024 | Dec 31, 2023 | 69.93M | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | 68.81M | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | 64.60M | May 11, 2023 |
| FY2021 | Dec 31, 2020 | 53.59M | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | 30.19M | Mar 31, 2022 |